What's Next In: Ingredients - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

What's Next In: Ingredients


Pharmaceutical Technology


5. S.S. Zhu et al., "Chiral Mo-Binol Complexes: Activity, Synthesis, and Structure. Efficient Enantioselective Six-Membered Ring Synthesis through Catalytic Metathesis," J. Am. Chem. Soc. 121 (36), 8251-8259 (1999).

6. R.R. Schrock and A.H. Hoveyda, "Molybdenum and Tungsten Imido Alkylidene Complexes as Efficient Olefin-Metathesis Catalysts," Angew. Chem., Int. Ed. 42 (38), 4592-4633 (2003).

7. A.H. Hoveyda and R.R. Schrock, "Catalytic Asymmetric Olefin Metathesis," Chem. Eur. J. 7 (5 ), 945-950 (2001).

8. T.J. Seiders, D.W. Ward, and R.H. Grubbs, "Enantioselective Ruthenium-Catalyzed Ring-Closing Metathesis," Org. Lett. 3 (20) 3225-3228 (2001).

9. J.J. Van Veldhuizen. "A Recyclable Chiral Ru Catalyst for Enantioselective Olefin Metathesis. Efficient Catalytic Asymmetric Ring-Opening/Cross Metathesis in Air," J. Am. Chem. Soc. 124 (18), 4954-4955 (2002).

10. J.J. Van Veldhuizen et al., "Chiral Ru-Based Complexes for Asymmetric Olefin Metathesis: Enhancement of Catalyst Activity through Steric and Electronic Modification," J. Am. Chem. Soc. 125 (41), 12502-12508 (2003).

11. D.G. Gillingham et al., "Efficient Enantioselective Synthesis of Functionalized Tetrahydropyrans by Ru-Catalyzed Asymmetric Ring-Opening Metathesis/Cross-Metathesis (AROM/CM)," J. Am. Chem. Soc. 126 (6), 12288-12290 (2004).

12. T.W. Funk, J.M. Berlin, and R.H. Grubbs, "A Highly Active Palladium Catalyst for Intermolecular Hydroamination. Factors that Control Reactivity and Additions of Functionalized Anilines to Dienes and Vinylarenes," J. Am. Chem. Soc. 128 (6), 1840-1846 (2006).

Industry experts give their predictions for the next 30 years. Read Editor-in-Chief Michelle Hoffman's introduction here. See what's next in:

Strategy and Regulation
Outsourcing
Solid-Dosage Formulation
Ingredients
Drug Delivery
Packaging
Analytical Testing
Information Technology


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here